UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Multiple sclerosis, 2022-05, Vol.28 (6), p.925-932

2022

Volltextzugriff (PDF)

Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy

Neurology, 2018-01, Vol.90 (1), p.e12

2018

Volltextzugriff (PDF)

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Current treatment options in neurology, 2016-01, Vol.18 (1), p.2-2, Article 2

2016

Volltextzugriff (PDF)

Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis

Journal of the neurological sciences, 2015-08, Vol.355 (1), p.59-63

2015

Volltextzugriff (PDF)

Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging

Multiple sclerosis, 2016-03, Vol.22 (3), p.302-311

2016

Volltextzugriff (PDF)

High risk of postpartum relapses in neuromyelitis optica spectrum disorder

Neurology, 2017-11, Vol.89 (22), p.2238

2017

Volltextzugriff (PDF)

In vivo identification of morphologic retinal abnormalities in neuromyelitis optica

Neurology, 2013-04, Vol.80 (15), p.1406

2013

Volltextzugriff (PDF)

Two‐year observational study of deferiprone in superficial siderosis

CNS neuroscience & therapeutics, 2018-03, Vol.24 (3), p.187-192

2018

Volltextzugriff (PDF)

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

Neurology : neuroimmunology & neuroinflammation, 2016-12, Vol.3 (6), p.e286-e286

2016

Volltextzugriff (PDF)

A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder

Medicine (Baltimore), 2019-06, Vol.98 (25), p.e15944-e15944

2019

Volltextzugriff (PDF)

Bevacizumab is safe in acute relapses of neuromyelitis optica

Clinical & experimental neuroimmunology, 2015-11, Vol.6 (4), p.413-418

2015

Volltextzugriff (PDF)

What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Clinical imaging, 2016-05, Vol.40 (3), p.573-580

2016

Volltextzugriff (PDF)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy

JAMA neurology, 2014-03, Vol.71 (3), p.324

2014

Volltextzugriff (PDF)

Racial differences in neuromyelitis optica spectrum disorder

Neurology, 2018-11, Vol.91 (22), p.e2089

2018

Volltextzugriff (PDF)

Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning

Multiple sclerosis, 2020-10, Vol.26 (11), p.1360-1371

2020

Volltextzugriff (PDF)

Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results

Journal of neurology, 2017-11, Vol.264 (11), p.2284-2292

2017

Volltextzugriff (PDF)

Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D

International journal of MS care, 2019-05, Vol.21 (3), p.129-134

2019

Volltextzugriff (PDF)

Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab

Journal of neuroimmunology, 2015-10, Vol.287, p.29-30

2015

Volltextzugriff (PDF)

Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder

Pain management nursing, 2019-12, Vol.20 (6), p.580-591

2019

Volltextzugriff (PDF)

Mortality in neuromyelitis optica is strongly associated with African ancestry

Neurology : neuroimmunology & neuroinflammation, 2018-07, Vol.5 (4), p.e468-e468

2018

Volltextzugriff (PDF)

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

Multiple sclerosis, 2018-11, Vol.24 (13), p.1737-1742

2018

Volltextzugriff (PDF)

Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD

Multiple sclerosis, 2021-10, Vol.27 (11), p.1738-1748

2021

Volltextzugriff (PDF)

2189 Scrambler therapy: Potential new treatment for central neuropathic pain?

Journal of clinical and translational science, 2018-06, Vol.2 (S1), p.47-47

2018

Volltextzugriff (PDF)

Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica

Neurology : neuroimmunology & neuroinflammation, 2014-06, Vol.1 (1), p.e5-e5

2014

Volltextzugriff (PDF)

TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders

Journal of the neurological sciences, 2017-02, Vol.373, p.303-306

2017

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(59)
Berichte
(1)

Sprache

Englisch
(60)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Neurosciences & Neurology
(42)
Clinical Neurology
(40)
Humans
(31)
Neurosciences
(23)
Female
(22)
Adult
(21)
Male
(21)
Middle Aged
(18)
Neuromyelitis Optica
(16)
Retrospective Studies
(14)
Aged
(13)
Adolescent
(12)
Neurology
(12)
Neuromyelitis
(11)
Neuromyelitis Optica - Drug Therapy
(11)
Young Adult
(11)
Aquaporin 4
(10)
Spinal Cord
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis

Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging

High risk of postpartum relapses in neuromyelitis optica spectrum disorder

In vivo identification of morphologic retinal abnormalities in neuromyelitis optica

Two‐year observational study of deferiprone in superficial siderosis

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder

Bevacizumab is safe in acute relapses of neuromyelitis optica

What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy

Racial differences in neuromyelitis optica spectrum disorder

Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning

Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results

Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D

Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab

Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder

Mortality in neuromyelitis optica is strongly associated with African ancestry

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders

Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD

2189 Scrambler therapy: Potential new treatment for central neuropathic pain?

Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica

TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders

Suchergebnisse filtern